HIMS launches Peptides+ with five clinically guided therapies, expanding personalized wellness care through tailored treatments and ongoing medical support.
Hims & Hers Health said it will now offer five new peptides and longevity treatments compounded in the U.S. as part of the initial rollout of its Peptides+ platform. The telehealth company will now offer compounded formulations of sermorelin, glutathione, and NAD+, as well as vitamin B-12 and L-carnitine, none of which are approved by the FDA.
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers (NYSE: HIMS) today announced the launch of Peptides+, a new specialty built around clinically-guided protocols designed to target health at the cellular level. After a clinical visit with a licensed provider, eligible customers may be prescribed a personalized treatment plan including up to five treatments at launch: Sermorelin, NAD+, Glutathione, Vitamin B12, and L-Carnitine, depending on their needs as determined by their provider. Access to BPC.
Hims & Hers Health is a Strong Buy: my $23.8 implied share price offers roughly 20% upside while targeting a 15% annual return. International expansion is the principal growth driver, with revenue guidance raised to at least $650 million in 2026 and $1 billion expected in 2027. HIMS faces near-term margin pressure and subscriber headwinds; Q3 gross margin fell to 57%, while subscribers declined by 103,000 sequentially.
Commonwealth Equity Services LLC reduced its position in shares of Hims and Hers Health, Inc. (NYSE: HIMS) by 16.1% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 283,323 shares of the company's stock after selling 54,365 shares during the quarter. Commonwealth
Hims & Hers stock is facing margin pressure as it increases sales of branded weight-loss drugs and expands internationally. The company has a big opportunity in the peptide market.
Hims & Hers unites with Lilly to offer FDA-approved weight-loss drugs, Zepbound and Foundayo, expanding patient access and strengthening its obesity care platform.